Impact of18F-florbetapir PET imaging of β-amyloid neuritic plaque density on clinical decision-making
- 3 April 2013
- journal article
- research article
- Published by Taylor & Francis in Neurocase
- Vol. 20 (4) , 466-473
Abstract
18F-florbetapir positron emission tomography (PET) imaging of the brain is now approved by the Food and Drug Administration (FDA) approved for estimation of β-amyloid neuritic plaque density when evaluating patients with cognitive impairment. However, its impact on clinical decision-making is not known. We present 11 cases (age range 67–84) of cognitively impaired subjects in whom clinician surveys were done before and after PET scanning to document the theoretical impact of amyloid imaging on the diagnosis and treatment plan of cognitively impaired subjects. Subjects have been clinically followed for about 5 months after the PET scan. Negative scans occurred in five cases, leading to a change in diagnosis for four patients and a change in treatment plan for two of these cases. Positive scans occurred in six cases, leading to a change in diagnosis for four patients and a change in treatment plan for three of these cases. Following the scan, only one case had indeterminate diagnosis. Our series suggests that both positive and negative florbetapir PET scans may enhance diagnostic certainty and impact clinical decision-making. Controlled longitudinal studies are needed to confirm our data and determine best practices.Keywords
This publication has 10 references indexed in Scilit:
- Potential Impact of Amyloid Imaging on Diagnosis and Intended Management in Patients With Progressive Cognitive DeclineAlzheimer Disease & Associated Disorders, 2013
- Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive declineNeurology, 2012
- Brain Amyloid Imaging — FDA Approval of Florbetapir F18 InjectionNew England Journal of Medicine, 2012
- Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort studyThe Lancet Neurology, 2012
- Amyloid deposition, hypometabolism, and longitudinal cognitive declineAnnals of Neurology, 2012
- Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010Journal of Neuropathology & Experimental Neurology, 2012
- What is the Utility of Amyloid Imaging From the Point of View of the clinician?Neurodegenerative Disease Management, 2011
- Use of Florbetapir-PET for Imaging β-Amyloid PathologyJAMA, 2011
- Clinical Criteria for the Diagnosis of Alzheimer Disease: Still Good After All These YearsThe American Journal of Geriatric Psychiatry, 2008
- Conversion to dementia from mild cognitive disorderNeurology, 2006